Bioactive Food Components as Activators of Human SIRT1; Development of Caloric Restriction-mimetic Therapeutics Type 2 Diabetes and Obesity

Type 2 Diabetes (T2D) has reached epidemic proportions in the United States. There are currently 18 million patients in North America and the National Institute of Diabetes and Digestive Kidney Disease (NIDDK) estimates that approximately 800,000 new cases of diabetes are diagnosed each year in the U.S. alone. In 2002 the direct costs of T2D were estimated to be $92 billion (up from $44 billion in 1997), constituting roughly 19% of the total health care expenditure of the U.S. The purpose of this study is to develop caloric-restriction mimetics for the treatment of type 2 diabetes.